ORKA: Oruka Therapeutics, Inc.
About
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Current Value
$22.221 Year Return
Current Value
$22.221 Year Return
Key Details
Market Cap
$780.47M
P/E Ratio
-3.74
1Y Stock Return
82.82%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
0.8
Strategies that include ORKA
Stock's related to ORKA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VNDA | 39.82% | $286.88M | +42.61% | 0.00% |
| SNDL | 33.05% | $525.69M | +33.78% | 0.00% |
| ABUS | 30.66% | $661.33M | +90.71% | 0.00% |
| AG | 26.33% | $2.01B | +21.76% | 0.28% |
| FSM | 26.15% | $1.51B | +32.33% | 0.00% |
| WT | 25.40% | $1.69B | +80.19% | 1.04% |
| PARA | 25.08% | $6.89B | -26.53% | 1.94% |
| PLAY | 25.01% | $1.39B | -7.92% | 0.00% |
| GRWG | 24.90% | $103.68M | -30.00% | 0.00% |
| PRIM | 24.74% | $4.37B | +163.90% | 0.30% |
| TLRY | 24.19% | $1.18B | -26.40% | 0.00% |
| GHM | 23.32% | $464.78M | +132.21% | 0.00% |
| ENLC | 22.99% | $7.13B | +20.56% | 3.39% |
| GE | 22.98% | $192.17B | +85.70% | 0.52% |
| ALDX | 22.79% | $294.18M | +102.46% | 0.00% |
| NOAH | 22.55% | $775.22M | -3.69% | 8.96% |
| BPT | 22.44% | $24.61M | -66.18% | 0.00% |
| MXL | 22.35% | $1.22B | -18.18% | 0.00% |
| NNE | 21.46% | $833.66M | +531.50% | 0.00% |
| OWL | 20.95% | $13.30B | +72.82% | 2.88% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AVA | 0.02% | $3.07B | +11.83% | 3.68% |
| JILL | 0.02% | $368.36M | -21.45% | 0.58% |
| BYRN | 0.05% | $479.70M | +295.19% | 0.00% |
| LPTX | -0.05% | $103.46M | +10.66% | 0.00% |
| MGRC | -0.05% | $2.89B | +20.25% | 1.60% |
| EXC | 0.06% | $39.29B | +0.57% | 3.88% |
| RLMD | 0.07% | $89.92M | +1.36% | 0.00% |
| RVNC | 0.08% | $394.43M | -47.99% | 0.00% |
| SRE | 0.08% | $59.15B | +28.15% | 2.62% |
| ETON | -0.09% | $271.28M | +195.77% | 0.00% |
| TCOM | -0.10% | $40.41B | +91.40% | 0.00% |
| LXRX | 0.10% | $318.44M | -18.44% | 0.00% |
| ALE | 0.11% | $3.73B | +17.43% | 4.38% |
| SOUN | 0.12% | $2.34B | +207.08% | 0.00% |
| CNP | -0.12% | $20.46B | +14.18% | 1.90% |
| CAPR | 0.12% | $839.37M | +532.19% | 0.00% |
| COLM | -0.12% | $4.70B | +9.93% | 1.11% |
| RIO | -0.12% | $78.19B | -11.12% | 6.94% |
| ARCC | 0.12% | $13.45B | - | 8.81% |
| MRK | 0.13% | $244.21B | -5.55% | 3.18% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ULTA | -30.42% | $16.12B | -15.50% | 0.00% |
| BIRK | -17.64% | $8.75B | +7.40% | 0.00% |
| DG | -13.86% | $16.82B | -37.95% | 3.17% |
| HUSA | -12.89% | $16.69M | -11.56% | 0.00% |
| CBOE | -12.63% | $21.46B | +15.84% | 1.11% |
| PG | -12.12% | $402.15B | +14.14% | 2.33% |
| DLTR | -12.07% | $13.95B | -44.11% | 0.00% |
| CNNE | -11.97% | $1.27B | +14.42% | 1.18% |
| CPB | -11.72% | $12.96B | +7.08% | 3.40% |
| BNED | -11.03% | $277.22M | -91.94% | 0.00% |
| ELF | -10.79% | $6.86B | +8.95% | 0.00% |
| MNST | -10.06% | $52.25B | -1.95% | 0.00% |
| SOL | -9.77% | $98.11M | -29.01% | 0.00% |
| TR | -9.71% | $2.33B | -0.74% | 1.10% |
| DDS | -9.69% | $6.90B | +31.38% | 0.24% |
| CHD | -9.69% | $27.18B | +19.50% | 1.03% |
| HRL | -9.31% | $16.30B | -8.38% | 3.81% |
| LFVN | -9.18% | $169.84M | +130.61% | 1.10% |
| KGS | -9.12% | $3.37B | +110.22% | 4.11% |
| HSY | -9.10% | $34.45B | -10.68% | 3.21% |
ETF's related to ORKA
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 32.15% | $273.87M | 0% |
| QQA | 24.97% | $135.01M | 0% |
| EFAA | 19.72% | $117.38M | 0% |
| HEQT | 18.77% | $254.30M | 0.53% |
| PEJ | 18.20% | $257.98M | 0.57% |
| BIBL | 17.85% | $336.19M | 0.35% |
| XLI | 17.17% | $21.95B | 0.09% |
| GRID | 17.16% | $1.94B | 0.57% |
| CALF | 16.96% | $8.93B | 0.59% |
| VIS | 16.93% | $5.85B | 0.1% |
| FIDU | 16.90% | $1.25B | 0.084% |
| FMDE | 16.87% | $2.02B | 0.23% |
| IWO | 16.85% | $12.56B | 0.24% |
| KOMP | 16.80% | $2.09B | 0.2% |
| SFYX | 16.77% | $105.21M | 0.06% |
| FNY | 16.69% | $372.31M | 0.7% |
| IPAY | 16.64% | $325.84M | 0.75% |
| IYJ | 16.56% | $1.64B | 0.39% |
| JMOM | 16.51% | $1.22B | 0.12% |
| BETZ | 16.48% | $79.19M | 0.75% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XHLF | <0.01% | $874.27M | 0.03% |
| IBD | -0.02% | $330.68M | 0.44% |
| RTH | -0.02% | $228.85M | 0.35% |
| FMHI | -0.04% | $747.15M | 0.7% |
| KRBN | -0.12% | $242.47M | 0.85% |
| GTIP | 0.18% | $136.50M | 0.12% |
| VNLA | -0.19% | $2.27B | 0.23% |
| FMB | 0.21% | $2.03B | 0.65% |
| YEAR | 0.23% | $1.13B | 0.25% |
| KXI | 0.25% | $695.03M | 0.41% |
| KMLM | -0.31% | $353.87M | 0.9% |
| LTPZ | -0.34% | $715.65M | 0.2% |
| FLRN | 0.39% | $2.33B | 0.15% |
| CGMU | -0.53% | $2.53B | 0.27% |
| FLMX | -0.54% | $91.21M | 0.19% |
| DBA | 0.63% | $755.88M | 0.93% |
| EDV | 0.64% | $3.88B | 0.06% |
| HYZD | -0.66% | $161.49M | 0.43% |
| EWH | -0.77% | $641.56M | 0.5% |
| VRP | 0.79% | $1.83B | 0.5% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -11.95% | $195.31M | 0.85% |
| TAIL | -10.40% | $67.98M | 0.59% |
| NFLT | -10.24% | $199.18M | 0.5% |
| BTAL | -10.22% | $388.04M | 1.43% |
| FLDR | -10.04% | $595.01M | 0.15% |
| TPMN | -9.58% | $40.60M | 0.65% |
| XBIL | -8.88% | $637.70M | 0.15% |
| MUST | -8.04% | $410.00M | 0.23% |
| CSHI | -8.00% | $482.85M | 0.38% |
| PREF | -7.91% | $999.92M | 0.55% |
| MUNI | -7.65% | $1.73B | 0.35% |
| FLMI | -7.65% | $356.19M | 0.3% |
| UUP | -7.55% | $309.25M | 0.77% |
| SHYD | -7.53% | $311.50M | 0.35% |
| PWZ | -7.41% | $697.36M | 0.28% |
| HTAB | -7.29% | $437.10M | 0.4% |
| DFNM | -7.23% | $1.40B | 0.17% |
| SGOV | -6.99% | $27.53B | 0.09% |
| USDU | -6.82% | $201.97M | 0.5% |
| XLP | -4.20% | $16.03B | 0.09% |
News
Yahoo
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced participation and a fireside chat at Piper Sandler’s 36th Annual Healthcare Conference: Date: Tuesday, December 3rd, 2024Time: 3:00PM ET About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set
Yahoo
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro potency data, presented at EADV in September, further support and derisk the program Strong execution allowed for acceleration of clinical timelines for both ORKA-001 and ORKA-002, as previously announced MENLO PARK, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq
Yahoo
MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences: Stifel 2024 Healthcare ConferenceDate: Monday, November 18th, 2024Time: 2:25PM ET Jefferies London Healthcare ConferenceDate: Wednesday, November 20th, 2024Time: 2:
Yahoo
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar binding affinity and epitope demonstrated in several preclinical assays MENLO PARK, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases includi
Yahoo
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $200 million to the Company
Yahoo
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human dosing now expected third quarter 2025 New preclinical data on ORKA-001 to be presented at EADV in September showing robust preclinical activity including a half-life in NHPs of over 30 days MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechn
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.